All vitamins with rda ,transport, storage, coenzyme function, key rxns , deficiency in tabular form

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have comprehensive data from multiple authoritative textbooks. Let me compile the complete vitamin table.

Here is the comprehensive vitamin reference table compiled from Harrison's Principles of Internal Medicine, Goldman-Cecil Medicine, Yamada's Textbook of Gastroenterology, Medical Physiology, and Henry's Clinical Diagnosis and Management by Laboratory Methods.

Complete Vitamin Reference Table

FAT-SOLUBLE VITAMINS (A, D, E, K)

Absorption & Transport (general): Absorbed in small intestine via chylomicrons → lymphatics → bloodstream. Stored in liver (A, D, K) and adipose/muscle (E). Bile and pancreatic lipase are required.

Vitamin	RDA (Adult)	Transport	Storage	Coenzyme / Active Form	Key Reactions	Deficiency
A (Retinol)	M: 900 μg/day F: 700 μg/day	Dietary retinyl esters absorbed into chylomicrons → lymph → plasma. Released from liver as retinol bound to retinol-binding protein (RBP) + transthyretin (TTR). β-carotene → retinol in intestinal wall.	Liver (≈90% as retinyl esters); small amounts in kidney, lung, adipose	Retinal (11-cis-retinal in rhodopsin); Retinoic acid (nuclear receptor ligand for gene expression)	1. Rhodopsin synthesis (11-cis-retinal + opsin) → phototransduction. 2. Retinoic acid → RAR/RXR nuclear receptors → epithelial differentiation & immune function. 3. Glycoprotein synthesis	Night blindness (earliest), xerophthalmia, Bitot's spots, keratomalacia (corneal ulceration), follicular hyperkeratosis ("toad skin"), increased susceptibility to infection
D (Cholecalciferol / D₃)	15 μg/day (600 IU); age >70: 20 μg/day	Dietary D₂/D₃ absorbed in chylomicrons → lymph. Skin-synthesised D₃ binds vitamin D–binding protein (DBP/GC-globulin) → liver. Circulates bound to DBP.	Liver, adipose, muscle (as 25-OH-D₃)	1,25-(OH)₂D₃ (calcitriol) — nuclear steroid hormone; no classic coenzyme role	1. Liver: D₃ → 25-OH-D₃ (calcidiol) by CYP2R1/27A1. 2. Kidney: 25-OH-D₃ → 1,25-(OH)₂D₃ (calcitriol) by CYP27B1 (regulated by PTH, PO₄). 3. Calcitriol → VDR → ↑ intestinal Ca²⁺/PO₄ absorption, ↑ renal reabsorption, bone mineralisation	Children: Rickets (epiphyseal widening, bowing, Harrison's sulcus). Adults: Osteomalacia (bone pain, proximal myopathy, pseudofractures). Contributes to osteoporosis and fracture risk
E (α-Tocopherol)	M: 15 mg/day F: 15 mg/day	Absorbed in chylomicrons → lymph. In plasma, distributed via LDL, HDL, VLDL. Liver preferentially retains α-tocopherol via α-tocopherol transfer protein (α-TTP)	Adipose tissue, liver, muscle; slow turnover	Not a classical coenzyme — acts as chain-breaking antioxidant	1. Scavenges lipid peroxyl radicals → prevents polyunsaturated fatty acid (PUFA) oxidation in cell membranes. 2. Protects RBC membranes. 3. Regenerated by vitamin C and glutathione. 4. Modulates platelet aggregation	Peripheral neuropathy (posterior column/spinocerebellar), hemolytic anemia (especially in premature infants), retinopathy. Rare in adults; seen in fat-malabsorption syndromes (abetalipoproteinemia, cholestatic liver disease)
K (K₁ = Phylloquinone; K₂ = Menaquinones; K₃ = Menadione)	M: 120 μg/day F: 90 μg/day	Absorbed with fat in chylomicrons → lymph → plasma. K₁ carried mainly by VLDL/LDL. K₂ produced by gut bacteria and absorbed in colon (minimal).	Liver (short-lived; no significant stores — this is why deficiency develops quickly)	γ-Carboxylation co-substrate: reduced (KH₂) form is cofactor for γ-glutamyl carboxylase	Carboxylation of glutamate residues (→ Gla residues) in: Clotting factors II, VII, IX, X (procoagulant); Protein C, Protein S (anticoagulant); Osteocalcin (bone matrix protein); Matrix Gla protein (vascular calcification inhibitor). Warfarin blocks vitamin K epoxide reductase (VKOR).	Hemorrhagic disease: prolonged PT/INR, easy bruising. Hemorrhagic disease of the newborn (neonates lack gut flora + breast milk is low in K). Also: neonates, fat-malabsorption, broad-spectrum antibiotics

WATER-SOLUBLE VITAMINS (B-complex + C)

Absorption & Transport (general): Freely absorbed in small intestine (mostly jejunum); circulate freely in plasma or loosely bound to albumin; minimal storage; regular intake required.

Vitamin	RDA (Adult)	Transport / Absorption	Storage	Coenzyme / Active Form	Key Reactions	Deficiency
B₁ (Thiamine)	M: 1.2 mg/day F: 1.1 mg/day Pregnancy: 1.4 mg/day	Active Na⁺-dependent transport at low doses (jejunum); passive diffusion at high doses. Phosphorylated inside cells. Transported as free thiamine in plasma; in RBCs as TPP.	Minimal (liver, heart, brain). Body stores last only 2–3 weeks.	Thiamine pyrophosphate (TPP) / Thiamine diphosphate (TDP)	1. Pyruvate dehydrogenase (pyruvate → acetyl-CoA) 2. α-Ketoglutarate dehydrogenase (α-KG → succinyl-CoA, TCA cycle) 3. Branched-chain α-keto acid dehydrogenase (BCAA catabolism) 4. Transketolase (pentose phosphate pathway)	Beriberi: • Dry: peripheral neuropathy (glove-and-stocking), wrist/foot drop • Wet: high-output cardiac failure, edema • Wernicke-Korsakoff syndrome (alcoholics): ophthalmoplegia, ataxia, confusion → amnesia. D-lactic acidosis (severe). Benfotiamine test: elevated erythrocyte transketolase activity
B₂ (Riboflavin)	M: 1.3 mg/day F: 1.1 mg/day Pregnancy: 1.4 mg/day	Active Na⁺-dependent transport (jejunum); phosphorylated to FMN inside enterocytes. Circulates as free riboflavin + FMN/FAD bound to proteins.	Minimal (liver).	FMN (Flavin mononucleotide) and FAD (Flavin adenine dinucleotide)	1. Electron carrier in mitochondrial ETC (Complex I: NADH dehydrogenase uses FMN; Complex II: succinate dehydrogenase uses FAD). 2. Fatty acid β-oxidation (FAD-dependent acyl-CoA dehydrogenase). 3. Glutathione reductase (FAD). 4. Required for activating B₆ and folate.	Ariboflavinosis: angular stomatitis (cheilosis), glossitis (magenta tongue), corneal vascularization, seborrheic dermatitis, normocytic anemia, photophobia. Signs often overlap with other B-vitamin deficiencies.
B₃ (Niacin / Nicotinic acid)	M: 16 NE/day F: 14 NE/day (1 NE = 1 mg niacin = 60 mg tryptophan)	Passive absorption (nicotinic acid/nicotinamide). Can be synthesised from tryptophan (60:1 ratio; requires B₂, B₆, iron). Circulates as NAD⁺/NADH, nicotinamide in plasma.	Minimal	NAD⁺/NADH and NADP⁺/NADPH	1. Glycolysis (GAPDH: NAD⁺ → NADH). 2. TCA cycle (isocitrate DH, α-KG DH, malate DH). 3. Fatty acid synthesis (NADPH). 4. Oxidative phosphorylation (NADH → ETC Complex I). 5. Sirtuin deacetylases (use NAD⁺).	Pellagra — 4 D's: Dermatitis (photosensitive, Casal's necklace), Diarrhea, Dementia, Death. Seen in corn-dominant diets (low tryptophan, niacin bound as niacytin). Also: Hartnup disease (tryptophan malabsorption), carcinoid syndrome (tryptophan diversion).
B₅ (Pantothenic acid)	M & F: 5 mg/day (AI) Pregnancy: 6 mg; Lactation: 7 mg	Passive diffusion and active transport (jejunum).	Minimal; widespread in all tissues.	Coenzyme A (CoA-SH) and Acyl carrier protein (ACP)	1. Acetyl-CoA formation → TCA cycle entry. 2. Fatty acid synthesis (ACP). 3. Fatty acid β-oxidation (CoA thioester activation). 4. Cholesterol and steroid hormone synthesis. 5. Acetylcholine synthesis. 6. Amino acid catabolism	Deficiency extremely rare (ubiquitous in foods — panto = "everywhere"). Burning feet syndrome (prisoners of war). Experimental: irritability, fatigue, GI disturbances, paresthesias.
B₆ (Pyridoxine / Pyridoxal / Pyridoxamine)	Adults 19–50: 1.3 mg/day >50: 1.7 mg (M), 1.5 mg (F) Pregnancy: 1.9 mg	Passive diffusion (jejunum); Na⁺-independent. Phosphorylated to PLP in liver and intestinal wall. Circulates as PLP bound to albumin and in RBCs.	Liver (as PLP); muscle glycogen phosphorylase contains largest body pool.	Pyridoxal phosphate (PLP)	1. Transamination (AST, ALT — amino acid interconversion). 2. Decarboxylation of amino acids (DOPA → dopamine; 5-HTP → serotonin; glutamate → GABA; histidine → histamine). 3. Glycogen phosphorylase (glycogenolysis). 4. Cystathionine β-synthase (homocysteine → cystathionine). 5. δ-ALA synthase (heme synthesis — rate-limiting step). 6. Sphingolipid synthesis.	Seborrheic dermatitis, microcytic anemia (sideroblastic — impaired heme synthesis), glossitis, peripheral neuropathy, epileptiform convulsions (especially in neonates), depression/confusion. Isoniazid (INH) and penicillamine chelate PLP → iatrogenic deficiency. Raised plasma homocysteine.
B₇ (Biotin)	Adults: 30 μg/day (AI) Lactation: 35 μg/day	Passive diffusion (jejunum). Avidin in raw egg whites irreversibly binds biotin in gut → blocks absorption.	Minimal; widely distributed.	Biocytin (biotin covalently linked to carboxylase enzymes via lysine residue)	As prosthetic group in 4 carboxylase enzymes: 1. Pyruvate carboxylase (pyruvate → oxaloacetate — gluconeogenesis/anaplerosis). 2. Acetyl-CoA carboxylase (acetyl-CoA → malonyl-CoA — fatty acid synthesis). 3. Propionyl-CoA carboxylase (propionyl-CoA → methylmalonyl-CoA). 4. β-Methylcrotonyl-CoA carboxylase (leucine catabolism).	Rare. Causes: raw egg whites (avidin), prolonged TPN without biotin, biotinidase deficiency. Signs: alopecia, seborrheic/exfoliative dermatitis, glossitis, anorexia, depression, hypercholesterolemia, metabolic acidosis (lactic acidosis from pyruvate carboxylase failure).
B₉ (Folate / Folic acid)	Adults: 400 μg DFE/day Pregnancy: 600 μg DFE/day Lactation: 500 μg DFE/day	Dietary polyglutamate forms hydrolyzed to monoglutamate by jejunal brush-border γ-glutamyl hydrolase → absorbed by proton-coupled folate transporter (PCFT). In plasma as 5-methyltetrahydrofolate (5-MTHF) bound loosely to albumin and by specific folate-binding proteins.	Liver (≈50% of total stores as polyglutamates); stores last ~3–4 months.	Tetrahydrofolate (THF) and its derivatives (5-MTHF, 10-formyl-THF, 5,10-methylene-THF)	1. Thymidylate synthase: 5,10-methylene-THF + dUMP → dTMP (DNA synthesis). 2. Purine synthesis: 10-formyl-THF donates C at steps 3 and 9. 3. Methionine cycle: 5-MTHF donates methyl group to homocysteine (via B₁₂) → methionine → SAM (methylation reactions). 4. Amino acid interconversion (serine↔glycine via serine hydroxymethyltransferase).	Megaloblastic anemia (impaired DNA synthesis → large, hypersegmented neutrophils). Neural tube defects (spina bifida, anencephaly) — periconceptional deficiency. Glossitis, hyperhomocysteinemia. Note: Neurological signs absent (unlike B₁₂ deficiency).
B₁₂ (Cobalamin)	Adults: 2.4 μg/day Pregnancy: 2.6 μg/day Lactation: 2.8 μg/day	Complex absorption: 1. Gastric acid/pepsin releases B₁₂ from food. 2. Binds haptocorrin (R protein) in stomach. 3. Pancreatic proteases release it in duodenum. 4. Binds intrinsic factor (IF) (from gastric parietal cells). 5. IF-B₁₂ complex absorbed by cubam receptor in terminal ileum. Circulates bound to transcobalamin II (TCII) (delivery to cells) and haptocorrin/transcobalamin I (storage form in plasma).	Liver (large stores — 2,000–5,000 μg; sufficient for 2–5 years).	Methylcobalamin (cytoplasm) and Adenosylcobalamin (mitochondria)	1. Methylcobalamin: Methionine synthase — 5-MTHF + homocysteine → methionine + THF (links folate and B₁₂ cycles; SAM synthesis). 2. Adenosylcobalamin: L-Methylmalonyl-CoA mutase — methylmalonyl-CoA → succinyl-CoA (odd-chain fatty acid & BCAA catabolism, TCA).	Megaloblastic (pernicious) anemia + Subacute combined degeneration of spinal cord (posterior + lateral columns → proprioception loss, spastic paraparesis). Glossitis, dementia, hyperhomocysteinemia, elevated methylmalonyl-CoA/methylmalonic acid (MMA). Causes: pernicious anemia (IF deficiency), gastrectomy, terminal ileal disease, veganism, metformin (↓ absorption).
C (Ascorbic acid)	Adults: 90 mg/day (M), 75 mg/day (F) Smokers: +35 mg/day	Passive diffusion at high doses; Na⁺-dependent SVCT1/SVCT2 transporters at physiological doses. Circulates freely in plasma; concentrated in leukocytes and adrenal gland.	Adrenal cortex, pituitary, liver (highest concentration). No major long-term storage — excess excreted.	Reducing agent / Electron donor — not a classical coenzyme but essential cofactor for hydroxylases	1. Prolyl & lysyl hydroxylases — proline/lysine hydroxylation in collagen synthesis (→ cross-linking; triple helix stability). 2. Dopamine-β-hydroxylase — dopamine → norepinephrine. 3. Trimethyllysine hydroxylase — carnitine synthesis. 4. Enhances iron absorption (Fe³⁺ → Fe²⁺ in gut). 5. Antioxidant (regenerates vitamin E). 6. Tyrosine catabolism (4-hydroxyphenylpyruvate dioxygenase).	Scurvy: perifollicular hemorrhages (corkscrew hairs), bleeding gums, ecchymoses, impaired wound healing, hyperkeratosis, Wimberger sign (scorbutic rosary on X-ray), osteoporosis, fatigue, emotional lability. Develops after ~3 months of deprivation.

Quick-Reference Summary Table

Vitamin	Active Coenzyme Form	Key Enzyme(s)	Classic Deficiency Disease
A	Retinal, Retinoic acid	Rhodopsin; RAR/RXR	Night blindness → Xerophthalmia
D	1,25-(OH)₂D₃ (Calcitriol)	VDR → calcium channels; PTH axis	Rickets / Osteomalacia
E	α-Tocopherol (antioxidant)	Glutathione peroxidase system support	Neuropathy, hemolytic anemia
K	KH₂ (hydroquinone)	γ-Glutamyl carboxylase	Hemorrhagic disease
B₁	TPP (thiamine pyrophosphate)	PDH, α-KGDH, transketolase	Beriberi / Wernicke-Korsakoff
B₂	FMN, FAD	ETC Complex I & II, β-oxidation	Ariboflavinosis (angular stomatitis)
B₃	NAD⁺/NADH, NADP⁺/NADPH	GAPDH, TCA dehydrogenases	Pellagra (4 D's)
B₅	CoA, ACP	Fatty acid synthase, TCA	Burning feet (rare)
B₆	PLP	Transaminases, δ-ALA synthase, decarboxylases	Sideroblastic anemia, neuropathy
B₇	Biocytin	Pyruvate carboxylase, ACC, PCC	Alopecia + dermatitis (rare)
B₉	THF (5-MTHF, etc.)	Thymidylate synthase, purine synthesis	Megaloblastic anemia + NTDs
B₁₂	Methylcobalamin, Adenosylcobalamin	Methionine synthase, MMA mutase	Megaloblastic anemia + SCD cord
C	Ascorbate (redox cofactor)	Prolyl/lysyl hydroxylase, DβH	Scurvy

Sources: Goldman-Cecil Medicine Table 199-2; Medical Physiology Table 45-3; Henry's Clinical Lab Methods Table 27.1; Yamada's Textbook of Gastroenterology Table 22.1; Harrison's Principles of Internal Medicine 22E

Key clinical mnemonics:

Fat-soluble vitamins (ADEK): stored long-term; toxicity possible with excess; require bile/fat for absorption
B₁₂ trap: B₁₂ deficiency traps folate as 5-MTHF (cannot convert to THF) → explains why both cause megaloblastic anemia but only B₁₂ causes neurological damage
INH steals B₆: isoniazid structurally resembles pyridoxal and competes for PLP → always co-prescribe pyridoxine
Coumarin/warfarin blocks VKOR → depletes active vitamin K → prevents γ-carboxylation of clotting factors II, VII, IX, X

All possible viva questions in Hii Metabolism.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive textbook data from Harrison's, Lippincott Biochemistry, and Harper's Biochemistry. I have everything needed to compile a thorough viva Q&A on heme metabolism.

Viva Questions: Heme Metabolism

Sources: Harrison's Principles of Internal Medicine 22E; Lippincott's Illustrated Biochemistry 8e; Harper's Illustrated Biochemistry 32e; Goldman-Cecil Medicine

SECTION 1 — HEME STRUCTURE & OVERVIEW

Q1. What is heme? Describe its structure. Heme is an iron-containing porphyrin — specifically protoporphyrin IX chelated with ferrous iron (Fe²⁺). The porphyrin ring is formed from four pyrrole rings connected by methylene bridges (tetrapyrrole). The iron sits in the centre of the ring, bound by four nitrogen atoms of the pyrroles. Heme is the prosthetic group of hemoglobin, myoglobin, respiratory cytochromes, and cytochrome P450 enzymes.

Q2. What is a porphyrin? How does it differ from a porphyrinogen? Porphyrins are fully oxidised tetrapyrroles with conjugated double bonds — they are coloured and fluoresce red under UV (Soret band ~400 nm). Porphyrinogens are the reduced (colourless) intermediates in heme synthesis. Porphyrins accumulate and cause toxicity in the porphyrias.

Q3. What percentage of daily heme synthesis occurs in erythroid tissue vs liver?

~85% — erythroid precursors (bone marrow); mostly for hemoglobin
~15% — hepatocytes; mostly for CYP450 enzymes
Mature RBCs cannot synthesise heme (lack mitochondria)

SECTION 2 — HEME BIOSYNTHESIS (The 8 Steps)

Q4. What are the starting substrates for heme synthesis? Glycine (provides all N and some C) + Succinyl-CoA (a TCA cycle intermediate). Condensation occurs in the mitochondria and requires pyridoxal phosphate (PLP/B₆) as coenzyme.

Q5. Name all 8 enzymes of heme biosynthesis in order. Where does each reaction occur?

Step	Enzyme	Location	Substrate → Product
1	ALA synthase (ALAS)	Mitochondria	Glycine + Succinyl-CoA → δ-ALA
2	ALA dehydratase (ALAD / PBG synthase)	Cytosol	2× ALA → PBG (porphobilinogen)
3	HMB synthase (PBG deaminase)	Cytosol	4× PBG → Hydroxymethylbilane (HMB)
4	Uroporphyrinogen III cosynthase	Cytosol	HMB → Uroporphyrinogen III
5	Uroporphyrinogen decarboxylase	Cytosol	Uroporphyrinogen III → Coproporphyrinogen III (4 acetate → 4 methyl)
6	Coproporphyrinogen oxidase	Mitochondria	Coproporphyrinogen III → Protoporphyrinogen IX
7	Protoporphyrinogen oxidase	Mitochondria	Protoporphyrinogen IX → Protoporphyrin IX
8	Ferrochelatase (heme synthase)	Mitochondria	Protoporphyrin IX + Fe²⁺ → Heme

Mnemonic for location: Steps 1 + 6,7,8 = Mitochondria; Steps 2–5 = Cytosol ("1 in, 4 out, 3 back in")

Q6. What is the rate-limiting and committed step in heme synthesis? Step 1: ALA synthase (ALAS). It catalyses the condensation of glycine + succinyl-CoA → δ-ALA. Requires PLP (B₆) as coenzyme.

Q7. What are the two isoforms of ALA synthase? How do they differ?

ALAS1 (housekeeping): expressed in all tissues, especially liver. Encoded on chromosome 3p21.1. Regulated by heme (negative feedback).
ALAS2 (erythroid-specific): expressed only in erythroid precursors. Encoded on chromosome Xp11.2. Regulated by intracellular iron availability (not by heme feedback).

Q8. How does heme regulate its own synthesis (feedback inhibition)? Heme (as hemin, Fe³⁺ form) inhibits ALAS1 by three mechanisms:

Represses transcription of the ALAS1 gene (via Egr-1 aporepressor + NAB corepressor)
Increases degradation of ALAS1 mRNA
Blocks import of ALAS1 into mitochondria

Because ALAS1 has a short half-life, this regulation is rapid and sensitive. ALAS2 is not feedback regulated by heme.

Q9. How do drugs precipitate porphyria attacks? Many drugs (barbiturates, sulfonamides, rifampicin, alcohol, oral contraceptives, etc.) are metabolised by hepatic CYP450 enzymes (hemoproteins). Their administration induces CYP450 synthesis → increased heme consumption → fall in free intracellular heme → loss of heme's feedback inhibition → ALAS1 upregulated → ALA and PBG accumulate → porphyria attack.

Q10. Why does glucose/carbohydrate intake prevent acute porphyria attacks ("glucose effect")? Fasting activates PGC-1α (peroxisome proliferator-activated receptor γ coactivator 1α) in the liver, which transcriptionally activates ALAS1 → increased porphyrin precursor production. Glucose/carbohydrates suppress PGC-1α → suppress ALAS1 → reduce ALA/PBG accumulation. This is the basis of glucose loading as emergency treatment.

Q11. What is the Soret band? What is its significance? A sharp absorption peak near 400 nm shared by all porphyrins. Used in spectrophotometric detection and quantification of porphyrins in urine/feces. Porphyrins also show red fluorescence under UV light — important in diagnosing porphyria cutanea tarda and EPP.

SECTION 3 — HEME CATABOLISM & BILIRUBIN METABOLISM

Q12. How is heme catabolised? Heme from degraded hemoglobin (and other hemoproteins) is degraded in the reticuloendothelial system (RES) — macrophages of liver, spleen, bone marrow:

Heme oxygenase (microsomal; substrate-inducible) cleaves the porphyrin ring → biliverdin + CO + Fe³⁺
- Requires 3 O₂ + 7 electrons (from NADPH via cytochrome P450 reductase)
- CO is a signalling molecule and anti-inflammatory
Biliverdin reductase reduces biliverdin (green) → bilirubin (yellow-orange) using NADPH

Production: ~250–350 mg bilirubin/day in adults; 1 g Hb → ~35 mg bilirubin.

Q13. Why is unconjugated bilirubin (UCB) insoluble? How is it transported in blood? UCB is lipophilic due to internal hydrogen bonding. It circulates bound to serum albumin (high-affinity site: ~25 mg/dL capacity). UCB is not filtered by the glomerulus and does not appear in urine. Drugs (salicylates, sulfonamides) can displace bilirubin from albumin → risk of kernicterus in neonates.

Q14. Describe bilirubin metabolism in the liver (3 steps).

Uptake: UCB dissociates from albumin → enters hepatocyte via facilitated diffusion → binds intracellular ligandin (Y protein) and Z protein
Conjugation: Bilirubin UDP-glucuronosyltransferase (bilirubin UGT, microsomal) adds 2 glucuronic acid molecules → bilirubin diglucuronide (conjugated bilirubin — water-soluble)
Secretion: Conjugated bilirubin (CB) is actively transported into bile canaliculi (rate-limiting step; energy-dependent) via the MRP2 transporter

Q15. What happens to bilirubin in the intestine?

CB is hydrolysed and reduced by gut bacteria → urobilinogen (colourless)
Most urobilinogen is oxidised to stercobilin → excreted in feces (brown colour)
~20% urobilinogen is reabsorbed → enters portal blood (enterohepatic circulation)
Liver re-excretes most; a small amount enters systemic circulation → filtered by kidney → excreted as urobilin (gives urine its yellow colour)

Q16. Why is conjugated bilirubin (CB) called "direct" bilirubin and UCB called "indirect"? In the van den Bergh reaction:

CB reacts directly with diazo reagent (water-soluble, no alcohol needed) → "direct" bilirubin
UCB requires addition of alcohol (to disrupt albumin binding and internal H-bonds) before reacting → "indirect" bilirubin

SECTION 4 — JAUNDICE

Q17. Classify jaundice with mechanisms and lab findings.

Type	Cause	Serum UCB	Serum CB	Urine Bilirubin	Urine Urobilinogen	Stool
Pre-hepatic (haemolytic)	Excess RBC destruction	↑↑	Normal	Absent (UCB not filtered)	↑↑	Normal/dark
Hepatic (hepatocellular)	Hepatitis, cirrhosis	↑	↑	Present	↓ or ↑	Pale/normal
Post-hepatic (obstructive)	Gallstone, pancreatic Ca	Normal/↑	↑↑	Present (choluria)	Absent	Pale (clay-coloured)

Q18. Why is there no bilirubin in urine in pre-hepatic jaundice? UCB is tightly bound to albumin → not filtered by the glomerulus. Only CB (water-soluble, not albumin-bound) is filtered and appears in urine as bilirubinuria ("choluria").

Q19. What is delta (δ) bilirubin (biliprotein)? In prolonged obstructive jaundice, CB covalently binds to albumin — this fraction is called delta bilirubin. It has a long half-life (equal to albumin ~20 days) and does not appear in urine. This explains the persistent jaundice even after relief of obstruction.

SECTION 5 — HYPERBILIRUBINAEMIA SYNDROMES

Q20. Classify the hereditary hyperbilirubinaemia syndromes.

Syndrome	Defect	Type of Bilirubin ↑	Key Features
Gilbert syndrome	↓ UGT1A1 (~30% retained)	UCB	Benign; triggered by fasting, stress, illness; normal liver biopsy
Crigler-Najjar type I	Complete absence of UGT1A1	UCB (>20 mg/dL)	Kernicterus, often fatal <15 months; phototherapy partial help; phenobarbital ineffective; liver transplant curative
Crigler-Najjar type II	Partial UGT1A1 deficiency	UCB (<20 mg/dL)	Less severe; responds to phenobarbital (induces residual UGT)
Dubin-Johnson syndrome	Defective MRP2 (canalicular CB transporter)	CB	Benign; black pigment in hepatocytes; ↑ urinary coproporphyrin I
Rotor syndrome	Defective hepatic CB uptake/storage (OATP1B1/1B3)	CB	Benign; no liver pigment; ↑ urinary coproporphyrin I + III

Q21. Why does phenobarbital help in Crigler-Najjar type II but not type I? Phenobarbital is a potent inducer of hepatic UGT1A1 enzyme synthesis. In type II, there is residual (partial) enzyme that can be upregulated. In type I, the enzyme is completely absent, so there is nothing to induce.

SECTION 6 — PORPHYRIAS

Q22. What are porphyrias? How are they classified? Porphyrias are a group of disorders caused by partial enzyme deficiencies in the heme biosynthesis pathway → accumulation of toxic porphyrin precursors or porphyrins.

Classification:

By site of overproduction: Hepatic (ALAS1 upregulated) vs Erythropoietic
By clinical presentation: Acute (neurovisceral) vs Cutaneous (photosensitivity)

Q23. Which enzyme is deficient in each porphyria?

Porphyria	Enzyme Deficient	Type	Key Feature
ALA Dehydratase–Deficient (ADP)	ALA dehydratase	Acute hepatic	Extremely rare; ↑↑ ALA, normal PBG
Acute Intermittent Porphyria (AIP)	HMB synthase (PBG deaminase)	Acute hepatic	Most common acute porphyria; ↑↑ ALA + PBG; no skin lesions
Hereditary Coproporphyria (HCP)	Coproporphyrinogen oxidase	Acute + cutaneous	↑ fecal coproporphyrin III
Variegate Porphyria (VP)	Protoporphyrinogen oxidase	Acute + cutaneous	↑ fecal protoporphyrin; "dual" porphyria
Porphyria Cutanea Tarda (PCT)	Uroporphyrinogen decarboxylase	Cutaneous hepatic	Most common porphyria overall; blistering
Congenital Erythropoietic (CEP)	Uroporphyrinogen III cosynthase	Cutaneous erythropoietic	Severe blistering; pink urine in diapers
Erythropoietic Protoporphyria (EPP)	Ferrochelatase	Cutaneous erythropoietic	Non-blistering photosensitivity; ↑ RBC protoporphyrin
X-Linked EPP (XLP)	ALAS2 gain-of-function	Cutaneous erythropoietic	Clinically similar to EPP

Q24. What are the clinical features of Acute Intermittent Porphyria (AIP)?

Neurovisceral: Colicky abdominal pain (most common, poorly localised), nausea, vomiting, constipation; no peritonism (neurological, not inflammatory)
Autonomic: Tachycardia, hypertension, sweating, urinary retention
Peripheral neuropathy: Predominantly motor axonal (proximal > distal; shoulders/arms first); can progress to respiratory paralysis
CNS: Anxiety, insomnia, hallucinations, paranoia, seizures, hyponatremia (SIADH)
Port-wine/dark urine (ALA and PBG on exposure to light)

Q25. What are the precipitating factors for AIP attacks?

Drugs: Barbiturates, sulfonamides, rifampicin, carbamazepine, phenytoin, oral contraceptives (especially progestins), alcohol
Hormones: Endogenous progesterone (luteal phase) — explains female predominance and premenstrual attacks
Nutritional: Fasting/caloric restriction (activates PGC-1α → ALAS1)
Others: Infections, surgery, stress, smoking

Q26. What is the first-line diagnostic test for an acute porphyria attack? Spot urine for porphobilinogen (PBG) using a random (single-void) sample. PBG is markedly elevated (not just mildly elevated) during acute attacks of AIP, HCP, and VP. If positive, add quantitative urine ALA, PBG, and creatinine. 24-hour collection is unnecessary.

Q27. How is an acute porphyria attack treated?

Remove precipitant (stop offending drugs, treat infection)
Carbohydrate loading: IV glucose (300–500 g/day) → suppresses PGC-1α → reduces ALAS1 → reduces ALA/PBG
IV Hemin (heme arginate): Most effective — exogenous heme directly inhibits ALAS1 (feedback); use early in severe attacks
Supportive: Pain management (opioids), beta-blockers (tachycardia/hypertension), seizure management (avoid inducing AEDs; use levetiracetam, magnesium)
Avoid unsafe drugs (refer to drug database at www.drugs-porphyria.org)

Q28. Why does AIP have no skin involvement while HCP and VP do? AIP causes accumulation of ALA and PBG — these are porphyrin precursors, not porphyrins, so they do not cause photosensitivity. HCP and VP accumulate actual porphyrins (coproporphyrin III and protoporphyrin respectively) which absorb UV and generate reactive oxygen species → skin damage.

Q29. What is lead poisoning's connection to heme metabolism? (2 enzyme targets) Lead inhibits two enzymes:

ALA dehydratase (step 2) — most sensitive; ↑ ALA in urine
Ferrochelatase (step 8) — ↑ zinc protoporphyrin (ZPP) in RBCs (zinc substitutes for iron) Result: microcytic/sideroblastic anemia, elevated erythrocyte ZPP (screening test), elevated urinary ALA. Clinical: basophilic stippling of RBCs.

Q30. What is the difference between ALAS1 mutation causing sideroblastic anemia vs EPP?

Loss-of-function ALAS2 mutation → X-linked sideroblastic anemia (XLSA): impaired heme synthesis in erythroid cells → iron accumulates in mitochondria of erythroblasts (ringed sideroblasts)
Gain-of-function ALAS2 mutation (exon 11) → X-linked EPP (XLP): excess protoporphyrin → photosensitivity

SECTION 7 — HIGH-YIELD "CURVEBALL" QUESTIONS

Q31. Why is pyridoxal phosphate (B₆) deficiency linked to sideroblastic anemia? PLP is a coenzyme for ALAS (step 1 of heme synthesis). PLP deficiency → reduced ALAS activity → impaired heme synthesis → iron is not incorporated into heme → accumulates as iron deposits in RBC mitochondria → sideroblastic anemia (ringed sideroblasts on iron stain). This is also why isoniazid (INH, which inactivates PLP) can cause sideroblastic anemia.

Q32. What is the "trap" between folate and heme metabolism? δ-ALA synthase (step 1) requires PLP. Succinyl-CoA (substrate) comes from methylmalonyl-CoA mutase which requires B₁₂ (adenosylcobalamin). So B₁₂ deficiency can impair heme synthesis via reduced succinyl-CoA.

Q33. Carbon monoxide (CO) is a byproduct of heme catabolism. What is its physiological role? CO produced by heme oxygenase-1 (HO-1) acts as a:

Vasodilator and smooth muscle relaxant (similar to NO)
Anti-inflammatory signalling molecule
Inhibitor of platelet aggregation HO-1 is also a stress-response enzyme (induced by oxidative stress, hypoxia, heavy metals)

Q34. Name the two bilirubin transporter proteins and the syndromes caused by their deficiency.

MRP2 (multidrug resistance protein 2) on canalicular membrane: deficiency → Dubin-Johnson syndrome (conjugated hyperbilirubinaemia; black hepatocyte pigment)
OATP1B1/1B3 on sinusoidal membrane (uptake): deficiency → Rotor syndrome

Q35. How does phototherapy work in neonatal jaundice? Blue light (wavelength 450–460 nm) converts lipophilic UCB to water-soluble geometric isomers (lumirubin and photo-bilirubin) via photo-isomerisation — these can be excreted in bile and urine without conjugation, bypassing the UGT step. This is the basis of phototherapy in neonatal hyperbilirubinaemia and Crigler-Najjar type I.

Q36. What is the Watson-Schwartz test? What does it detect? A qualitative screening test for urinary PBG. Ehrlich's reagent (p-dimethylaminobenzaldehyde) forms a pink-red aldehyde with PBG. Key: The pink complex with PBG is insoluble in chloroform (stays in aqueous phase), distinguishing it from urobilinogen (which extracts into chloroform) and from porphyrins.

Q37. What genetic mutation causes XLSA and what is the inheritance? X-linked recessive. Loss-of-function mutation in ALAS2 gene (Xp11.2). Since ALAS2 is not feedback-regulated by heme, there is no compensatory upregulation. Males are primarily affected; females are carriers (one normal X compensates).

QUICK VIVA MEMORY AIDS

Question	Answer
Rate-limiting enzyme of heme synthesis	ALA synthase (ALAS)
Coenzyme for ALAS	Pyridoxal phosphate (PLP/B₆)
Mitochondrial steps	1, 6, 7, 8
Cytosolic steps	2, 3, 4, 5
Most common acute porphyria	AIP (HMB synthase deficiency)
Most common porphyria overall	PCT (uroporphyrinogen decarboxylase)
Porphyria with no skin lesions	AIP (ALA/PBG accumulate, not porphyrins)
Enzyme inhibited by lead	ALAD (step 2) + Ferrochelatase (step 8)
Enzyme inhibited by hemin (feedback)	ALAS1
Bilirubin conjugated with	Glucuronic acid (×2)
Enzyme conjugating bilirubin	Bilirubin UGT (induced by phenobarbital)
Green pigment	Biliverdin
Reduced biliverdin →	Bilirubin (by biliverdin reductase, NADPH)
UCB transport in plasma	Albumin (high-affinity site)
CB transport into bile	MRP2 (active, rate-limiting)
Watson-Schwartz test detects	Urinary PBG
First-line test for acute porphyria	Spot urine PBG
Emergency treatment of AIP	IV glucose + IV hemin
Glucose effect works via	Suppressing PGC-1α → ↓ ALAS1
Dubin-Johnson defect	MRP2 transporter (canalicular CB secretion)
Rotor syndrome defect	OATP1B1/1B3 (sinusoidal uptake)

All all viva questions of nucleotide metabolism.

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive textbook data from Lippincott Biochemistry 8e, Basic Medical Biochemistry 6e, Harrison's, and Janeway's Immunobiology. I have everything needed to compile the complete viva.

Viva Questions: Nucleotide Metabolism

Sources: Lippincott's Illustrated Biochemistry 8e; Basic Medical Biochemistry 6e; Harrison's Principles of Internal Medicine 22E; Cellular & Molecular Immunology (Janeway's)

SECTION 1 — FUNDAMENTALS

Q1. What is the difference between a nucleoside, nucleotide, and nucleic acid?

Nucleobase = purine or pyrimidine ring alone
Nucleoside = nucleobase + pentose sugar (ribose or 2'-deoxyribose) linked by N-glycosidic bond
Nucleotide = nucleoside + ≥1 phosphate group at 5'-carbon
Nucleic acid = polymer of nucleotides linked by 3'→5' phosphodiester bonds

Q2. Name the purines and pyrimidines. Which bases are in DNA vs RNA?

	Purines (double ring)	Pyrimidines (single ring)
DNA	Adenine (A), Guanine (G)	Cytosine (C), Thymine (T)
RNA	Adenine (A), Guanine (G)	Cytosine (C), Uracil (U)

Mnemonic: Pur-ine = PURe As Gold (AG); CUT the PYrimidines (CUT — C, U, T)

Q3. What is PRPP? Why is it so important in nucleotide metabolism? 5-Phosphoribosyl-1-pyrophosphate (PRPP) is the activated ribose-5-phosphate donor. It is synthesised from ribose-5-phosphate + ATP by PRPP synthetase (X-linked; activated by inorganic phosphate; inhibited by purine nucleotides). PRPP is used in:

De novo purine synthesis (committed step)
De novo pyrimidine synthesis (adding ribose to orotic acid)
Purine salvage (HGPRT, APRT)
Pyrimidine salvage
NAD⁺ synthesis

Q4. What is the difference between de novo synthesis and the salvage pathway?

De novo: Building nucleotides from small precursor molecules (amino acids, CO₂, folate derivatives). Energetically expensive (≥6 ATP per purine). Major site: liver.
Salvage: Recycling preformed bases/nucleosides back to nucleotides using PRPP. Energetically cheap. Used by most peripheral tissues (brain, RBCs, leukocytes). Brain and erythrocytes rely almost exclusively on salvage.

SECTION 2 — PURINE DE NOVO SYNTHESIS

Q5. Where does de novo purine synthesis primarily occur? Where is the ring built? Mainly in the liver; also brain. The ring is built directly on PRPP (ribose-5-phosphate moiety), atom by atom. The free purine base is never an intermediate — purines are built as nucleotides from the start.

Q6. What are the precursor atoms of the purine ring? Name the source of each position.

Atom in ring	Source
N1	Aspartate
C2	N¹⁰-formyl-THF
N3	Glutamine
C4	Glycine
C5	Glycine
C6	CO₂
N7	Glycine
C8	N¹⁰-formyl-THF
N9	Glutamine

Mnemonic: "Go Go Gas Glutamine Aspartate Friends" — Glycine (C4,C5,N7), CO₂ (C6), 2× formyl-THF (C2,C8), 2× Glutamine (N3,N9), Aspartate (N1)

Q7. What is the committed step of purine synthesis? What enzyme catalyses it? The committed step is the formation of 5-phosphoribosylamine from PRPP + glutamine (N9 is added). Enzyme: Glutamine:PRPP amidotransferase (GPAT). Inhibited by AMP and GMP (end-product feedback inhibition); activated by PRPP (substrate availability). This is step 1 after PRPP formation.

Note: PRPP synthesis is NOT the committed step — PRPP is used in multiple other pathways.

Q8. What is the first purine nucleotide synthesised de novo? What is it the parent compound for? IMP (inosine monophosphate) — whose base is hypoxanthine. IMP is synthesised in 10 steps total (11 reactions including PRPP synthesis). IMP is then the branch point from which both AMP and GMP are synthesised.

Q9. How many ATP molecules are consumed in de novo purine synthesis (to reach IMP)? At least 6 high-energy phosphate bonds per IMP synthesised (4 direct ATPs + 2 from GTP). This high cost is why the salvage pathway is preferred when available.

Q10. How is AMP synthesised from IMP? How is GMP synthesised from IMP?

IMP → AMP:
1. IMP + aspartate + GTP → adenylosuccinate (adenylosuccinate synthase)
2. Adenylosuccinate → AMP + fumarate (adenylosuccinate lyase)
- Note: GTP is used to make AMP
IMP → GMP:
1. IMP + NAD⁺ → XMP (IMP dehydrogenase, rate-limiting)
2. XMP + glutamine + ATP → GMP + AMP (GMP synthetase)
- Note: ATP is used to make GMP

Cross-regulation: GTP drives AMP synthesis; ATP drives GMP synthesis — ensures balanced production.

Q11. How is purine synthesis regulated? Three levels:

PRPP synthetase: inhibited by purine nucleotides (AMP, GMP, IMP) — controls PRPP availability
GPAT (committed step): inhibited by AMP and GMP (end-product inhibition)
Branch point regulation:
- AMP feedback inhibits adenylosuccinate synthase
- GMP feedback inhibits IMP dehydrogenase
- Ensuring balanced AMP:GMP ratio

SECTION 3 — PURINE SALVAGE PATHWAY

Q12. Name the two key enzymes of the purine salvage pathway and their substrates.

Enzyme	Substrate (free base)	Product
HGPRT (hypoxanthine-guanine phosphoribosyltransferase)	Hypoxanthine → IMP; Guanine → GMP	Uses PRPP
APRT (adenine phosphoribosyltransferase)	Adenine → AMP	Uses PRPP

Both reactions: Base + PRPP → Nucleotide + PPi

Q13. What is the purine nucleotide cycle? Where is it important? A cycle in skeletal muscle involving:

AMP + aspartate → adenylosuccinate (adenylosuccinate synthase)
Adenylosuccinate → AMP + fumarate (adenylosuccinate lyase)
AMP → IMP + NH₃ (AMP deaminase)

Net effect: Deamination of aspartate → fumarate (anaplerotic substrate for TCA cycle). During intense exercise, fumarate replenishes TCA intermediates and enables rapid energy production. Deficiency of AMP deaminase causes myopathic fatigue.

Q14. What does adenosine deaminase (ADA) do? What is the clinical significance of ADA deficiency? ADA catalyses: Adenosine → inosine (and 2'-deoxyadenosine → 2'-deoxyinosine) via deamination. Deficiency → accumulation of deoxyadenosine → dATP → dATP inhibits ribonucleotide reductase → blocks dNTP synthesis for all nucleotides → cells cannot make DNA → arrest and apoptosis of lymphocytes. Developing lymphocytes are especially sensitive (inefficient dATP degradation).

Clinical: Autosomal recessive SCID (ADA-SCID) — most common cause of autosomal recessive SCID. Features: profound lymphopenia (T and B cells), recurrent opportunistic infections, costochondral abnormalities, deafness, liver damage. Treatment: enzyme replacement therapy (PEG-ADA), bone marrow transplant, gene therapy (first successful gene therapy in humans).

SECTION 4 — PURINE DEGRADATION & URIC ACID

Q15. Describe the pathway of purine degradation to uric acid (step by step).

AMP → (AMP deaminase) → IMP
IMP → (5'-nucleotidase) → Inosine
Inosine → (purine nucleoside phosphorylase, PNP) → Hypoxanthine + ribose-1-P

GMP → (5'-nucleotidase) → Guanosine
Guanosine → (PNP) → Guanine + ribose-1-P
Guanine → (guanase/guanine deaminase) → Xanthine

Hypoxanthine → (xanthine oxidase, XO) → Xanthine
Xanthine → (xanthine oxidase, XO) → Uric acid

Key enzyme: Xanthine oxidase (XO) — molybdenum-containing flavoprotein; uses O₂ as electron acceptor; produces H₂O₂ (reactive oxygen species). Target of allopurinol.

Q16. What is uric acid? Why is it the end product of purine catabolism in humans? Uric acid is the final oxidation product of xanthine in humans. Humans and higher primates lack uricase (urate oxidase), the enzyme that converts uric acid → allantoin (a more soluble compound). Most other mammals have uricase, so they can degrade uric acid further. This explains why humans are uniquely susceptible to gout.

Q17. What is the normal serum uric acid level? What defines hyperuricemia? Normal: 2.5–7.0 mg/dL (men); 1.5–6.0 mg/dL (women). Serum urate is close to its solubility limit (~6.8 mg/dL at physiological pH). Hyperuricemia: >7.0 mg/dL in men; >6.0 mg/dL in women.

SECTION 5 — GOUT

Q18. Define gout. What is the pathophysiology? Gout is a disorder characterised by hyperuricemia leading to deposition of monosodium urate (MSU) crystals in joints and periarticular tissues, triggering an acute inflammatory arthritis. Crystals activate neutrophils and the NLRP3 inflammasome → IL-1β release → intense inflammation.

Q19. What are the two main mechanisms of hyperuricemia?

Mechanism	Frequency	Examples
Underexcretion of uric acid	>90% of cases	Idiopathic; thiazide/loop diuretics; chronic kidney disease; lactic acidosis (lactate competes with urate at renal transporter); lead nephropathy (saturnine gout)
Overproduction of uric acid	<10% of cases	Lesch-Nyhan syndrome; PRPP synthetase superactivity; myeloproliferative disorders; tumour lysis syndrome; G6P deficiency (von Gierke)

Q20. How does von Gierke disease (G6P deficiency / glycogen storage disease type I) cause gout? In G6P deficiency, glucose-6-phosphate accumulates → shunted into pentose phosphate pathway → excess ribose-5-phosphate → excess PRPP → increased de novo purine synthesis → increased uric acid. Also, increased lactate (from excess pyruvate) competes with urate at the renal tubular transporter → reduced uric acid excretion. Both mechanisms combine to cause gout.

Q21. Describe the clinical features of gout.

Acute gouty arthritis: Exquisitely painful, red, swollen, warm joint (most commonly 1st metatarsophalangeal joint = podagra); typically nocturnal onset; self-limiting in days
Intercritical gout: Asymptomatic periods between attacks
Chronic tophaceous gout: Nodular deposits of MSU crystals (tophi) in soft tissues (ear pinnae, Achilles tendon, extensor tendons)
Urolithiasis: Uric acid kidney stones (radiolucent on X-ray; radiopaque on CT)
Urate nephropathy

Q22. How is gout diagnosed definitively? Polarised light microscopy of synovial fluid (or tophus material): shows needle-shaped, negatively birefringent (yellow when parallel to the polariser axis) MSU crystals, often within neutrophils. This is the gold standard. Hyperuricemia alone does not diagnose gout.

Q23. What are the treatments for gout?

Acute attack: Anti-inflammatory agents — colchicine (inhibits microtubule polymerisation → ↓ neutrophil migration; no effect on urate), NSAIDs (indomethacin), corticosteroids
Long-term urate-lowering therapy (ULT) — target urate <6 mg/dL:
- Allopurinol (XO inhibitor; structural analogue of hypoxanthine; first-line): oxidised to oxypurinol (long-lived suicide inhibitor of XO) → hypoxanthine and xanthine accumulate (more soluble); hypoxanthine salvaged via HGPRT → reduces PRPP → reduces de novo synthesis
- Febuxostat (non-purine XO inhibitor; used if allopurinol not tolerated)
- Probenecid, sulfinpyrazone (uricosuric agents — block renal urate reabsorption; used in underexcretors)
- Rasburicase (recombinant uricase — used in tumour lysis syndrome)

Q24. Why does allopurinol paradoxically reduce de novo purine synthesis in patients with functional HGPRT? When allopurinol inhibits XO, hypoxanthine accumulates. Hypoxanthine is salvaged by HGPRT → IMP. Increased IMP (and GMP) → feedback inhibits GPAT (the committed step of de novo synthesis). Also, consumption of PRPP by HGPRT reduces PRPP availability for de novo synthesis.

SECTION 6 — LESCH-NYHAN SYNDROME

Q25. What is Lesch-Nyhan syndrome? What is the enzyme defect? X-linked recessive disorder caused by near-complete deficiency of HGPRT (hypoxanthine-guanine phosphoribosyltransferase). Affects males.

Q26. What is the biochemical mechanism causing hyperuricemia in Lesch-Nyhan? Without HGPRT:

Hypoxanthine and guanine cannot be salvaged → degraded to uric acid → gout and urolithiasis
PRPP is not consumed by salvage → PRPP accumulates
IMP and GMP are not produced from salvage → less feedback inhibition on GPAT
Both effects → massive upregulation of de novo purine synthesis → excess AMP/GMP → excess uric acid

Q27. What are the clinical features of Lesch-Nyhan syndrome?

Hyperuricemia with severe gout, uric acid nephrolithiasis, renal failure
Neurological: Intellectual disability, developmental delay
Choreoathetosis, spasticity
Self-injurious behaviour (compulsive self-biting of lips and fingers) — pathognomonic; due to dopaminergic pathway dysfunction in the basal ganglia (HGPRT highly expressed in dopaminergic neurons)

Partial HGPRT deficiency (Kelley-Seegmiller syndrome) → gout and uric acid stones without neurological features

SECTION 7 — PYRIMIDINE SYNTHESIS

Q28. How does pyrimidine de novo synthesis differ from purine synthesis?

Feature	Purines	Pyrimidines
Ring built on	PRPP (as nucleotide from start)	Free ring first, then attached to PRPP
Site of synthesis	Mainly liver	All tissues (first 3 steps are cytosolic in liver; also occurs in all dividing cells)
Product added to PRPP	Purine nucleotide directly	Orotate (free base) → OMP → UMP
Key regulated enzyme	GPAT	CPS-II (first step)

Q29. What are the precursors of the pyrimidine ring? Only 3 sources (much simpler than purines):

Carbamoyl phosphate (provides C2, N3 — contributes N and CO₂)
Aspartate (provides the rest of the ring: N1, C4, C5, C6)
The C4–C5 double bond and C6 come from aspartate

Q30. Describe the de novo pyrimidine synthesis pathway step by step.

Glutamine + CO₂ + 2ATP → Carbamoyl phosphate — catalysed by CPS-II (cytosolic; rate-limiting; inhibited by UTP, activated by PRPP)
Carbamoyl phosphate + aspartate → carbamoylaspartate (aspartate transcarbamoylase, ATCase)
Carbamoylaspartate → dihydroorotate (dihydroorotase) — ring closure
Dihydroorotate → orotate (dihydroorotate dehydrogenase; on inner mitochondrial membrane; uses FMN)
Orotate + PRPP → OMP (orotate phosphoribosyltransferase) — here PRPP adds ribose to the base
OMP → UMP (OMP decarboxylase) — steps 5 & 6 catalysed by bifunctional enzyme UMP synthase

Steps 1–3 and 5–6 are cytosolic; step 4 is mitochondrial

UMP → UDP → UTP
UTP + glutamine → CTP (CTP synthetase)

Q31. What is the committed and rate-limiting step of pyrimidine synthesis? How is it regulated? CPS-II (carbamoyl phosphate synthetase II) — cytosolic, uses glutamine as nitrogen source.

Inhibited by: UTP (end-product)
Activated by: PRPP and ATP Note: CPS-I (mitochondrial, uses NH₃) is the urea cycle enzyme — completely different. CPS-II is specific to pyrimidine synthesis.

Q32. How is UMP converted to dTMP? Why is this clinically important?

UMP → UDP → dUDP (ribonucleotide reductase) → dUMP
Thymidylate synthase: dUMP + N⁵,N¹⁰-methylene-THF → dTMP + DHF (dihydrofolate)
- THF acts as both the methyl group donor AND hydrogen donor → oxidised to DHF
DHF reductase (DHFR): DHF → THF (regeneration; requires NADPH)

Clinical importance:

5-Fluorouracil (5-FU): converted to 5-FdUMP, a suicide inhibitor of thymidylate synthase → blocks dTMP → no DNA synthesis → antitumour
Methotrexate: inhibits DHFR → THF not regenerated → blocks both dTMP synthesis AND purine synthesis (folate trapping) → antitumour, anti-inflammatory

Q33. How are pyrimidines degraded? How does this differ from purines? The pyrimidine ring is cleaved open (unlike purines, whose ring is conserved and excreted as uric acid). Products are highly water-soluble:

CMP, UMP degradation: → β-alanine + CO₂ + NH₃
TMP (dTMP) degradation: → β-aminoisobutyrate + CO₂ + NH₃

These soluble end products are easily excreted. Therefore, pyrimidine excess does NOT cause gout.

SECTION 8 — DEOXYRIBONUCLEOTIDE SYNTHESIS

Q34. How are deoxyribonucleotides made? What enzyme is responsible? Ribonucleotide reductase (RNR) reduces all four ribonucleoside diphosphates (ADP, GDP, CDP, UDP) to the corresponding deoxy-NDPs by replacing the 2'-OH with H. Uses thioredoxin as hydrogen donor (regenerated by thioredoxin reductase + NADPH). Target of hydroxyurea (antineoplastic; also used in sickle cell disease to ↑ HbF).

Q35. How is ribonucleotide reductase regulated? Complex allosteric regulation via two sites on the R1 subunit:

Site	Effector	Effect
Overall activity site	ATP	Activates all reductions
Overall activity site	dATP	Inhibits all reductions — shuts down entire enzyme
Substrate specificity site	ATP/dATP	Favours CDP, UDP reduction
Substrate specificity site	dTTP	Favours GDP reduction
Substrate specificity site	dGTP	Favours ADP reduction

dATP at the activity site is the master off-switch — explains SCID in ADA deficiency (dATP accumulates → RNR inhibited → all dNTPs depleted → lymphocytes cannot divide)

SECTION 9 — DISORDERS OF NUCLEOTIDE METABOLISM

Q36. What is hereditary orotic aciduria? Describe its mechanism and treatment. A rare autosomal recessive disorder due to deficiency of UMP synthase (either or both of its enzymatic activities: orotate phosphoribosyltransferase and OMP decarboxylase). Result: orotate accumulates → orotic acid in urine. Also causes megaloblastic anemia (insufficient pyrimidines for DNA synthesis → impaired RBC maturation). Treatment: Uridine supplementation — bypasses the block; also provides UTP which feedback inhibits CPS-II, reducing further orotic acid synthesis.

Q37. Why does OTC (ornithine transcarbamoylase) deficiency also cause orotic aciduria? In the urea cycle, OTC transfers carbamoyl phosphate to ornithine. In OTC deficiency, carbamoyl phosphate (made by CPS-I in mitochondria) accumulates → leaks into cytoplasm → enters pyrimidine synthesis pathway via CPS-II bypass → floods the pathway → excess orotate → orotic aciduria. Distinction: no megaloblastic anemia (unlike hereditary orotic aciduria), but hyperammonemia is the dominant feature. Urine orotic acid elevated in both — differentiated by clinical context and ammonia levels.

Q38. What is purine nucleoside phosphorylase (PNP) deficiency? What immune defect does it cause? PNP converts inosine → hypoxanthine and guanosine → guanine. Deficiency → accumulation of deoxyguanosine → dGTP accumulates → inhibits RNR → impairs DNA synthesis in T lymphocytes specifically (T cells are sensitive to dGTP toxicity). Causes a form of SCID with predominant T-cell deficiency (unlike ADA deficiency which affects both T and B cells). Also features autoimmune hemolytic anemia and progressive neurologic deterioration.

SECTION 10 — DRUGS TARGETING NUCLEOTIDE METABOLISM

Q39. Summarise the antimetabolite drugs and their targets in nucleotide metabolism.

Drug	Target	Mechanism	Clinical Use
Allopurinol	Xanthine oxidase (XO)	Structural analogue of hypoxanthine → competitive inhibitor; oxidised to oxypurinol → suicide inhibitor of XO	Gout (overproducers)
Febuxostat	Xanthine oxidase	Non-purine XO inhibitor	Gout (allopurinol intolerant)
Hydroxyurea	Ribonucleotide reductase	Inhibits RNR → blocks dNTP synthesis	Cancer (melanoma, CML); sickle cell disease
5-Fluorouracil (5-FU)	Thymidylate synthase	→ 5-FdUMP (suicide inhibitor) → blocks dUMP → dTMP → ↓ DNA	Colorectal, breast cancer
Methotrexate	DHFR	Blocks DHF → THF recycling → ↓ folate pool → ↓ dTMP AND ↓ purine synthesis	Cancer; rheumatoid arthritis; psoriasis
6-Mercaptopurine (6-MP)	Multiple (GPAT, adenylosuccinate synthase, IMP dehydrogenase)	Converted to 6-thio-IMP → inhibits de novo purine synthesis + incorporation into nucleic acids	Leukemia
Azathioprine	Same as 6-MP (prodrug)	Converted to 6-MP in vivo	Immunosuppression (organ transplants, IBD)
Acyclovir	Viral DNA polymerase	Purine analogue; phosphorylated by viral thymidine kinase → inhibits viral DNA polymerase	Herpes simplex virus
AZT (zidovudine)	Viral reverse transcriptase	Pyrimidine (thymidine) analogue → chain terminator	HIV
Rasburicase	Uric acid (uricase)	Converts uric acid → allantoin (soluble)	Tumour lysis syndrome

SECTION 11 — HIGH-YIELD INTEGRATIVE & CURVEBALL QUESTIONS

Q40. Compare purine and pyrimidine synthesis — key differences.

Feature	Purine	Pyrimidine
Ring built on	PRPP (assembled on ribose)	Free ring → attached to PRPP later
End product of degradation	Uric acid (insoluble, causes gout)	β-alanine, β-aminoisobutyrate (soluble)
Rate-limiting enzyme	GPAT	CPS-II
Requires folate	Yes (2 steps using N¹⁰-formyl-THF)	Yes (dTMP synthesis via thymidylate synthase)
Clinical significance of excess	Gout	Orotic aciduria (not gout)

Q41. Why is the brain heavily dependent on the purine salvage pathway? The brain lacks significant de novo purine synthesis capacity. It depends on HGPRT and APRT to salvage preformed hypoxanthine and adenine arriving via the circulation. This explains why HGPRT deficiency (Lesch-Nyhan) causes severe neurological dysfunction even though gout (from overproduction) affects all tissues — dopaminergic neurons in the basal ganglia are especially HGPRT-dependent.

Q42. Why does ADA deficiency cause SCID but not affect most other cell types severely? ADA is expressed in all cells, but lymphocytes are uniquely inefficient at degrading dATP. When ADA is absent, deoxyadenosine accumulates → phosphorylated to dATP → inhibits RNR (via dATP binding to activity site) → blocks synthesis of ALL dNTPs → DNA synthesis halts → lymphocytes cannot proliferate. Non-lymphoid cells have other metabolic escape routes and more efficient dATP breakdown.

Q43. Folate deficiency blocks nucleotide synthesis — explain via which step. Folate (as N⁵,N¹⁰-methylene-THF) donates the methyl group in thymidylate synthase (dUMP → dTMP) and (as N¹⁰-formyl-THF) donates carbons C2 and C8 in purine ring synthesis. Deficiency → impaired dTMP AND purine nucleotide synthesis → reduced DNA synthesis → megaloblastic anemia. This is also the mechanism by which methotrexate (DHFR inhibitor) and 5-FU (thymidylate synthase inhibitor) are cytotoxic.

Q44. How does tumour lysis syndrome cause acute hyperuricemia? Massive chemotherapy-induced tumour cell death → release of large amounts of intracellular purine nucleotides → rapid degradation by XO → surge of uric acid → precipitation in renal tubules → acute kidney injury + gout. Prevention/treatment: allopurinol (prophylactic) or rasburicase (converts uric acid → allantoin, much more soluble; preferred in high-risk patients).

Q45. What is the significance of PRPP synthetase "superactivity" mutations? Gain-of-function mutations in X-linked PRPP synthetase can cause:

Increased Vmax (maximum rate of PRPP production)
Decreased Km for ribose-5-phosphate (higher affinity)
Decreased sensitivity to purine nucleotide inhibition (allosteric resistance)

All three mechanisms → excess PRPP → excess de novo purine synthesis → hyperuricemia and gout with onset in childhood/adolescence; some patients also have neurological features (sensorineural deafness, ataxia, hypotonia).

QUICK REVISION TABLE

Topic	Key Fact
Purine ring source atoms	Gly (C4,C5,N7), CO₂ (C6), 2× formyl-THF (C2,C8), 2× Gln (N3,N9), Asp (N1)
Pyrimidine ring source atoms	Carbamoyl phosphate + Aspartate
PRPP formed from	Ribose-5-P + ATP (by PRPP synthetase)
Committed step of purines	PRPP + Gln → PRA (GPAT enzyme)
First purine nucleotide	IMP (hypoxanthine base)
AMP synthesis from IMP requires	GTP
GMP synthesis from IMP requires	ATP
Committed step of pyrimidines	Gln + CO₂ → carbamoyl phosphate (CPS-II)
Rate-limiting pyrimidine step	CPS-II (inhibited by UTP, activated by PRPP)
dTMP synthesis enzyme	Thymidylate synthase (N⁵,N¹⁰-methylene-THF donor)
End product of purine catabolism	Uric acid
End products of pyrimidine catabolism	β-alanine, β-aminoisobutyrate (soluble)
XO inhibited by	Allopurinol (→ oxypurinol, suicide inhibitor)
HGPRT deficiency	Lesch-Nyhan syndrome (gout + self-mutilation + intellectual disability)
ADA deficiency	SCID (dATP ↑ → RNR inhibited → T and B cell aplasia)
PNP deficiency	T-cell SCID + autoimmune hemolytic anemia
UMP synthase deficiency	Hereditary orotic aciduria (orotic acid in urine + megaloblastic anemia)
OTC deficiency orotic aciduria	No megaloblastic anemia; hyperammonemia present
Ribonucleotide reductase inhibitor	Hydroxyurea; dATP (physiological off-switch)
Thymidylate synthase inhibitor	5-FU (→ 5-FdUMP, suicide inhibitor)
DHFR inhibitor	Methotrexate, trimethoprim

This is a shared conversation. Sign in to Orris to start your own chat.